Amgen Inc. $AMGN Shares Sold by PKO Investment Management Joint Stock Co

Key Points

• PKO Investment Management cut its stake in Amgen by 36.6% in Q4, selling 14,160 shares and retaining 24,500 shares worth about $8.02 million; roughly 76.5% of Amgen is held by institutions.
• Q1 results beat expectations: Amgen reported $5.15 EPS and $8.62 billion in revenue, and set FY2026 guidance at $21.70–$23.10 EPS (consensus ~22.28), a view many read as broadly in line with estimates.
• Amgen announced a $2.52 quarterly dividend (annualized $10.08, yield ~3.1%, ex-dividend May 15), but analyst views are mixed (consensus "Hold", average target $357.54) and the stock faces regulatory risk after the FDA proposed withdrawing Tavneos approval.

PKO Investment Management Joint Stock Co decreased its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 36.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 24,500 shares of the medical research company's stock after selling 14,160 shares during the period. PKO Investment Management Joint Stock Co's holdings in Amgen were worth $8,019,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Souders Financial Advisors raised its holdings in Amgen by 1.7% during the fourth quarter. Souders Financial Advisors now owns 5,328 shares of the medical research company's stock worth $1,744,000 after purchasing an additional 88 shares in the last quarter. Legacy Edge Advisors LLC purchased a new stake in Amgen in the 4th quarter valued at approximately $503,000. Pittenger & Anderson Inc. increased its position in Amgen by 3.1% during the 4th quarter. Pittenger & Anderson Inc. now owns 2,973 shares of the medical research company's stock worth $973,000 after purchasing an additional 90 shares during the period. Hussman Strategic Advisors Inc. acquired a new position in Amgen during the 4th quarter worth approximately $2,749,000. Finally, Ellis Investment Partners LLC raised its stake in shares of Amgen by 21.9% during the 4th quarter. Ellis Investment Partners LLC now owns 3,445 shares of the medical research company's stock worth $1,128,000 after buying an additional 620 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Stock Performance

NASDAQ AMGN opened at $329.82 on Friday. The business has a 50 day moving average price of $358.07 and a 200 day moving average price of $340.79. The company has a market capitalization of $178.00 billion, a P/E ratio of 22.95, a PEG ratio of 3.26 and a beta of 0.44. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts' consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a return on equity of 139.90% and a net margin of 20.96%.Amgen's quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the business earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Sell-side analysts expect that Amgen Inc. will post 22.28 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 3.1%. Amgen's payout ratio is currently 70.84%.

Analysts Set New Price Targets

A number of research firms recently weighed in on AMGN. Freedom Capital downgraded Amgen from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 12th. Barclays started coverage on Amgen in a research report on Friday, February 20th. They issued an "equal weight" rating and a $350.00 price objective for the company. Wells Fargo & Company raised their target price on Amgen from $375.00 to $390.00 and gave the company an "equal weight" rating in a report on Thursday, March 19th. Royal Bank Of Canada boosted their target price on shares of Amgen from $360.00 to $370.00 and gave the stock an "outperform" rating in a research report on Tuesday, April 7th. Finally, Oppenheimer set a $400.00 price target on shares of Amgen and gave the stock an "outperform" rating in a research note on Thursday, January 29th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $357.54.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q1 results beat expectations — AMGN reported $5.15 EPS vs. $4.73 consensus and product sales rose ~4%, with 16 drugs delivering double‑digit growth, supporting the company’s growth story. Amgen's Q1 Earnings Top Estimates
• Positive Sentiment: Bullish analyst action — Goldman Sachs reiterated a Buy and lifted its price target to $425, signaling long‑term upside from execution and pipeline momentum. Goldman Sachs Raises PT to $425
• Positive Sentiment: Other supportive analyst notes — Some firms (e.g., William Blair) reiterated Buy ratings after the quarter, highlighting confidence in the MariTide/weight‑loss program and execution. Analyst Reiterates Buy
• Neutral Sentiment: Guidance set but roughly in line — Amgen updated FY‑2026 EPS guidance to $21.70–$23.10 (consensus ~22.29), which many read as broadly in‑line rather than materially bullish. Amgen FY2026 Guidance (press release/slide)
• Neutral Sentiment: Small, mixed analyst target moves — Truist nudged its target to $327 with a Hold rating (minimal change), leaving some investors watching for clearer directional signals. Truist Raises PT to $327
• Negative Sentiment: FDA action risk — The FDA proposed withdrawing Tavneos approval after alleging clinical‑trial data issues, raising regulatory, compliance and reputational concerns that can pressure the stock. FDA Tavneos Proposal Coverage
• Negative Sentiment: Investor apprehension over strategy/timing — Some market commentary framed the quarter as “generally in‑line” and expressed concern about Amgen’s aggressive push into obesity (MariTide) and the near‑term profit impact, contributing to selling pressure. Investor Reaction to MariTide Expansion

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.